US Edition
News from oncnursingnews.com
We’ve assigned a media bias rating of unknown to oncnursingnews.com. You can read more about our methodology here.
If you want to know if oncnursingnews.com is credible or reliable, look no further. We rank oncnursingnews.com as Unknown factuality. Find out more about our methodology here.
Information about oncnursingnews.com
Where is oncnursingnews.com located?oncnursingnews.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top oncnursingnews.com News
Breast Cancer · United StatesOn Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET). The FDA approval is based on the results of the EMBER-3 trial in the patient populatio…See the Story
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer - Eli Lilly (NYSE:LLY)
60% Center coverage: 5 sources
FDA · United StatesCombination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination...See the Story
FDA Approves Roche’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
75% Center coverage: 4 sources
CancerPanelists discuss how intravenous administration of immune checkpoint inhibitors creates operational challenges including infusion chair bottlenecks, complex scheduling, venous access difficulties, and time burdens for patients, while subcutaneous formulations offer potential solutions through simplified delivery, reduced infusion center strain, and improved patient convenience.See the Story
